(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 3.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.96%.
Fortrea Holdings's revenue in 2024 is $3,109,000,000.On average, 3 Wall Street analysts forecast FTRE's revenue for 2024 to be $278,440,233,600, with the lowest FTRE revenue forecast at $270,033,594,000, and the highest FTRE revenue forecast at $282,870,540,000. On average, 3 Wall Street analysts forecast FTRE's revenue for 2025 to be $288,313,748,400, with the lowest FTRE revenue forecast at $275,251,872,000, and the highest FTRE revenue forecast at $296,745,420,000.
In 2026, FTRE is forecast to generate $310,568,984,400 in revenue, with the lowest revenue forecast at $304,661,968,800 and the highest revenue forecast at $316,476,000,000.